2,6-Dihydroxyacetophenone

Synonyms: 2,6-二羟基苯乙酮
2,6-Dihydroxyacetophenone 是一种苯乙酮 (Acetophenone (MS-H84138)) 的多酚衍生物,也是一种具有口服活性的 mTOR 抑制剂,具有抗氧化活性,可抑制结直肠癌 (CRC) 细胞的生长和增殖,使细胞周期停滞在 G0/G1 期,诱导结直肠癌 (CRC) 细胞凋亡 (apoptosis) 并抑制其迁移,同时抑制黄嘌呤氧化酶 (XOD)(IC50 为 1.24 mM),还可改善高尿酸血症小鼠的尿酸代谢、降低高胆固醇血症大鼠的血浆胆固醇、抑制高脂饮食诱导的肥胖小鼠的脂质积累,因此可用于结直肠癌 (CRC)、高尿酸血症和高胆固醇血症的研究。
产品编号: MS-Z28999 纯度: 99.85% CAS No.: 699-83-2 分子式: C8H8O3 分子量: 152.15
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
3-5 天
100g
询价
3-5 天
250g
询价
3-5 天
> 100g
询价
询价

产品描述

2,6-Dihydroxyacetophenone 是一种苯乙酮 (Acetophenone (MS-H84138)) 的多酚衍生物,也是一种具有口服活性的 mTOR 抑制剂,具有抗氧化活性,可抑制结直肠癌 (CRC) 细胞的生长和增殖,使细胞周期停滞在 G0/G1 期,诱导结直肠癌 (CRC) 细胞凋亡 (apoptosis) 并抑制其迁移,同时抑制黄嘌呤氧化酶 (XOD)(IC50 为 1.24 mM),还可改善高尿酸血症小鼠的尿酸代谢、降低高胆固醇血症大鼠的血浆胆固醇、抑制高脂饮食诱导的肥胖小鼠的脂质积累,因此可用于结直肠癌 (CRC)、高尿酸血症和高胆固醇血症的研究。

生物实验数据

生物活性 2,6-Dihydroxyacetophenone, a polyphenol derivative of acetophenone (Acetophenone (MS-H84138)), is an orally active mTOR inhibitor with antioxidant activity that inhibits the growth and proliferation of colorectal cancer (CRC) cells, arrests the cell cycle at the G0/G1 phase, induces apoptosis and suppresses the migration of colorectal cancer (CRC) cells, inhibits xanthine oxidase (XOD) with an IC50 of 1.24 mM, and ameliorates uric acid metabolism in hyperuricemic mice, lowers plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in high-fat diet-induced obese mice, and can therefore be used for research on colorectal cancer (CRC), hyperuricemia, and hypercholesterolemia.
体外研究
(In Vitro)

2,6-Dihydroxyacetophenone (5-40 µM,48 h) 抑制 HCT8 细胞的生长和增殖。
2,6-Dihydroxyacetophenone (10-100 µM,24-48 h) 使 HCT8 细胞的细胞周期停滞在 G0/G1 期,诱导凋亡并抑制细胞迁移。
2,6-Dihydroxyacetophenone (40 µM,48 h) 降低 HCT8 细胞中 p70S6K1 和 AKT1 的表达。
2,6-Dihydroxyacetophenone (0.1-2 mM) 抑制黄嘌呤氧化酶 (XOD),其 IC50 为 1.24 mM。
2,6-Dihydroxyacetophenone (200 µM,48 h) 降低 BRL 3A 细胞的存活率。
2,6-Dihydroxyacetophenone (0.325-1.3 mM, 24 h) 可抑制游离脂肪酸诱导的 LO2 细胞内脂质蓄积,且 1.3 mM 时能降低细胞内甘油三酯水平。

Cell Viability Assay

Cell Line: HCT8 cells
Concentration: 5, 10, 20, 40 μM
Incubation Time: 48 h
Result: Inhibited cell growth and proliferation of HCT8 cells.

Cell Cycle Analysis

Cell Line: HCT8 cells
Concentration: 40 μM
Incubation Time: 24 h
Result: Arrested HCT8 cells in G0/G1 phase of cell cycle with a 10% reduction in the percentage in the G2/M phase.

Apoptosis Analysis

Cell Line: HCT8 cells
Concentration: 40, 80, 100 μM
Incubation Time: 48 h
Result: Reduced the BCL2 expression.
Induced the BID expression.
Reduced the expression of p70S6K1 and AKT1.

Cell Migration Assay

Cell Line: HCT8 cells
Concentration: 10, 20, 40 μM
Incubation Time: 48 h
Result: Suppressed colorectal cancer cell migration.
体内研究
(In Vivo)

2,6-dihydroxyacetophenone (40 mM/kg,灌胃,每日一次,21 天) 可改善高尿酸血症小鼠的尿酸代谢紊乱。
2,6-dihydroxyacetophenone (60.86 mg/kg (400 μmol/kg),灌胃,每日两次,3 周) 能降低高胆固醇血症大鼠的血浆胆固醇水平。
2,6-dihydroxyacetophenone (7 mg/kg,灌胃,每日一次,8 周) 可抑制高脂饮食 (HFD) 诱导的肥胖小鼠的脂质蓄积。

Animal Model: A hyperuricemia (HUA) mouse model (8-week male Kunming mice), which was established by daily intragastric administration of Hypoxanthine (MS-W52610) (500 mg/kg), intraperitoneal injection of Potassium oxonate (MS-H10322) (300 mg/kg), and supplementation with 10% fructose water.
Dosage: 40 mM/kg
Administration: i.g. daily for 21 days
Result: Reduced serum UA levels in HUA mice.
Inhibited XOD activity in serum and liver.
Decreased serum CRE and BUN levels.
Improved renal tissue inflammatory infiltration and renal tubular lesions.
Increased the relative abundance of Lactobacillus.
Reduced the proportion of Firmicutes, and the abundance of Proteobacteria and Actinobacteria.
Regulated the gut microbiota structure.
Had no significant effect on the body weight and liver and kidney coefficients of mice.
Animal Model: Adult male Sprague-Dawley rats (weighing 200-250g) were fed a high-cholesterol diet containing 1.5% cholesterol and 0.5% cholic acid for 3 weeks to induce hypercholesterolemia.
Dosage: 60.86 mg/kg (400 μmol/kg)
Administration: i.g. twice daily for 3 weeks
Result: Decreased Plasma cholesterol levels in hypercholesterolemic rats significantly after 2 weeks treatment, and this effect persisted until the 3rd week.
Decreased the plasma cholesterol to 152 mg/dl.
Animal Model: Male and female KM mice (4 weeks) received high-fat diet (DIO series diets, 60% H10060).
Dosage: 7 mg/kg
Administration: i.g. daily for 8 weeks
Result: Caused a decreasing trend in body weight gain of mice compared with the HFD group.
Reduced the serum levels of triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) in mice.
Decreased the atherosclerosis index (AI) and coronary artery risk index (CRI) of mice.
Reversed the HFD-induced gut microbiota dysbiosis in mice.
Increased the relative abundance of the genus Odoribacter in the gut of mice.
Decreased the abundances of the genera Helicobacter and Mucispirillum in the gut of mice.
Reduced the HFD-induced increase in the Firmicutes/Bacteroidetes ratio in the gut of mice.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 152.15
分子式 C8H8O3
CAS No. 699-83-2
别名 2,6-二羟基苯乙酮

储存&溶解度

储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (657.25 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM6.5725 mL32.8623 mL65.7246 mL164.3115 mL
5 mM1.3145 mL6.5725 mL13.1449 mL32.8623 mL
10 mM0.6572 mL3.2862 mL6.5725 mL16.4312 mL
15 mM0.4382 mL2.1908 mL4.3816 mL10.9541 mL
20 mM0.3286 mL1.6431 mL3.2862 mL8.2156 mL
25 mM0.2629 mL1.3145 mL2.6290 mL6.5725 mL
30 mM0.2191 mL1.0954 mL2.1908 mL5.4771 mL
40 mM0.1643 mL0.8216 mL1.6431 mL4.1078 mL
50 mM0.1314 mL0.6572 mL1.3145 mL3.2862 mL
60 mM0.1095 mL0.5477 mL1.0954 mL2.7385 mL
80 mM0.0822 mL0.4108 mL0.8216 mL2.0539 mL
100 mM0.0657 mL0.3286 mL0.6572 mL1.6431 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础